Drug Trial Radar · NCT07406685
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Aug 31, 2030
Study completion Oct 31, 2030
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Taiwan University
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.
Conditions
- Postmenopausal Osteoporosis
- Postmenopausal Osteopenia
- Primary Osteoporosis
- Osteoporosis
Interventions
Ibandronate IVDrug
Ibandronate 3mg/3months for 12 months
Zoledronic acid IVDrug
Zoledronic acid 5mg/1year for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in bone mineral density (BMD)Time frame: Baseline to 24 months after treatment initiation.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.